Armando de Oliveira Schubach Selected Research

Leishmaniasis

1/2024	Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis.
1/2021	Serine proteases profiles of Leishmania (Viannia) braziliensis clinical isolates with distinct susceptibilities to antimony.
1/2019	Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report.
11/2018	Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions.
12/2017	Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
1/2015	Are Neutrophil Extracellular Traps Playing a Role in the Parasite Control in Active American Tegumentary Leishmaniasis Lesions?
4/2010	kDNA minicircle signatures of Leishmania (Viannia) braziliensis in oral and nasal mucosa from mucosal leishmaniasis patients.
12/2004	Identification of Leishmania (Leishmania) chagasi isolated from healthy skin of symptomatic and asymptomatic dogs seropositive for leishmaniasis in the municipality of Rio de Janeiro, Brazil.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Armando de Oliveira Schubach Research Topics

Disease

12	Cutaneous Leishmaniasis 01/2021 - 05/2005
8	Leishmaniasis 01/2024 - 12/2004
2	Visceral Leishmaniasis (Kala Azar) 07/2008 - 12/2004
1	Hearing Loss (Hearing Impairment) 01/2024
1	Ototoxicity 01/2024
1	Tinnitus 01/2024
1	Sporotrichosis 01/2019
1	Communicable Diseases (Infectious Diseases) 12/2017
1	Varicose Ulcer (Ulcer, Venous) 04/2017
1	Wounds and Injuries (Trauma) 04/2017
1	Ulcer 04/2017
1	Eczema 07/2014
1	Infections 07/2014
1	Hemorrhage 07/2014
1	Pathologic Complete Response 11/2008

Drug/Important Bio-Agent (IBA)

14	Meglumine AntimoniateIBA 01/2024 - 05/2005
2	Pentamidine (NebuPent)FDA LinkGeneric 01/2019 - 03/2011
2	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 04/2010
2	Immunoglobulin G (IgG)IBA 01/2009 - 07/2008
1	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2019
1	Melanins (Melanin)IBA 01/2019
1	Prednisone (Sone)FDA LinkGeneric 04/2017
1	AntimonyIBA 01/2017
1	Histones (Histone)IBA 01/2015
1	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2015
1	SteroidsIBA 07/2014
1	Kinetoplast DNA (kDNA)IBA 04/2010
1	AntibodiesIBA 01/2009
1	EnzymesIBA 01/2009
1	Itraconazole (Sporanox)FDA LinkGeneric 11/2008
1	AntigensIBA 07/2008
1	IsoenzymesIBA 12/2004

Therapy/Procedure

4	Therapeutics 04/2017 - 08/2012
1	Complementary Therapies (Alternative Medicine) 12/2017
1	Intralesional Injections 03/2017
1	Injections 01/2015
1	Aftercare (After-Treatment) 01/2015
1	Contraindications 08/2012
1	Euthanasia (Mercy Killing) 12/2004